Zoledronic Acid

Kathy Wilkinson

Angie Osborne

treatment decision making
CJON 2002, 6(6), 365-366. DOI: 10.1188/02.CJON.365-366

Zoledronic acid inhibits the resorption of mineralized bone and cartilage. It inhibits the increased osteoclastic activity and skeletal calcium that is induced by stimulatory factors released by malignant tumors. Zoledronic acid is indicated for the treatment of hypercalcemia, multiple myeloma, and osteolytic metastases in solid tumors. Clinical trials are ongoing for zoledronic acid use in osteoporosis, secondary to osteoarthritis and Paget’s disease.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.